Viridian Therapeutics, Inc. (VRDN)
VRDN Stock Price Chart
Explore Viridian Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VRDN price movements and trends.
VRDN Company Profile
Discover essential business fundamentals and corporate details for Viridian Therapeutics, Inc. (VRDN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jun 2014
Employees
143.00
CEO
Stephen F. Mahoney
Description
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
VRDN Financial Timeline
Browse a chronological timeline of Viridian Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$1.02, while revenue estimate is $28.00k.
Earnings released on 5 May 2026
EPS came in at -$0.90 surpassing the estimated -$1.06 by +15.09%, while revenue for the quarter reached $141.00k , beating expectations by +290.77%.
Earnings released on 26 Feb 2026
EPS came in at -$1.08 falling short of the estimated -$0.90 by -20.00%, while revenue for the quarter reached $132.00k , missing expectations by -99.28%.
Earnings released on 5 Nov 2025
EPS came in at -$0.34 surpassing the estimated -$0.82 by +58.54%, while revenue for the quarter reached $70.57m , beating expectations by +348.06%.
Earnings released on 6 Aug 2025
EPS came in at -$1.00 matching the estimated -$1.00, while revenue for the quarter reached $75.00k .
Earnings released on 6 May 2025
EPS came in at -$0.87 surpassing the estimated -$0.95 by +8.42%, while revenue for the quarter reached $72.00k , beating expectations by +63.34%.
Earnings released on 27 Feb 2025
EPS came in at -$0.81 surpassing the estimated -$1.05 by +22.86%, while revenue for the quarter reached $72.00k , beating expectations by +44.00%.
Earnings released on 12 Nov 2024
EPS came in at -$1.15 falling short of the estimated -$1.06 by -8.49%, while revenue for the quarter reached $86.00k , beating expectations by +72.00%.
Earnings released on 8 Aug 2024
EPS came in at -$1.02 falling short of the estimated -$0.89 by -14.61%, while revenue for the quarter reached $72.00k , missing expectations by -10.00%.
Earnings released on 8 May 2024
EPS came in at -$0.79 surpassing the estimated -$1.10 by +28.18%, while revenue for the quarter reached $72.00k , beating expectations by +2.86%.
Earnings released on 27 Feb 2024
EPS came in at -$1.35 falling short of the estimated -$1.00 by -35.00%, while revenue for the quarter reached $72.00k , missing expectations by -53.30%.
Earnings released on 13 Nov 2023
EPS came in at -$1.09 surpassing the estimated -$1.27 by +14.17%, while revenue for the quarter reached $72.00k , missing expectations by -55.00%.
Earnings released on 8 Aug 2023
EPS came in at -$1.27 surpassing the estimated -$1.29 by +1.55%, while revenue for the quarter reached $72.00k , missing expectations by -28.00%.
Earnings released on 9 May 2023
EPS came in at -$1.61 falling short of the estimated -$1.02 by -57.84%, while revenue for the quarter reached $98.00k , missing expectations by -2.00%.
Earnings released on 8 Mar 2023
EPS came in at -$1.13 falling short of the estimated -$0.73 by -54.79%, while revenue for the quarter reached $105.00k , missing expectations by -79.41%.
Earnings released on 14 Nov 2022
EPS came in at -$0.86 surpassing the estimated -$1.02 by +15.69%, while revenue for the quarter reached $1.20m , beating expectations by +293.96%.
Earnings released on 15 Aug 2022
EPS came in at -$1.06 falling short of the estimated -$0.90 by -17.78%, while revenue for the quarter reached $256.00k , missing expectations by -5.30%.
Earnings released on 12 May 2022
EPS came in at -$0.98 surpassing the estimated -$1.08 by +9.26%, while revenue for the quarter reached $216.00k , missing expectations by -14.79%.
Earnings released on 10 Mar 2022
EPS came in at -$1.32 falling short of the estimated -$0.85 by -55.29%, while revenue for the quarter reached $214.00k , missing expectations by -37.57%.
Earnings released on 4 Nov 2021
EPS came in at -$1.25 surpassing the estimated -$1.47 by +14.97%, while revenue for the quarter reached $208.00k , missing expectations by -63.51%.
Earnings released on 11 Aug 2021
EPS came in at -$2.21 falling short of the estimated -$1.52 by -45.39%, while revenue for the quarter reached $1.09m , beating expectations by +42.88%.
VRDN Stock Performance
Access detailed VRDN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
